Zumagev (astuprotimut-R) / Agenus, GSK - LARVOL DELTA

Immunotherapy in lung cancer. (PubMed) - "Whole tumor vaccines have also been evaluated in lung cancer and influence the patient's immune system to allow recognition of the tumor as foreign creating de novo immunity. This review summarizes the evidence to date for the efficacy and safety of immunotherapies in lung cancer."

Journal • Biosimilar • Immunology • Melanoma • Non Small Cell Lung Cancer • Oncology

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (clinicaltrials.gov) - P1/2; N=16; Terminated; Sponsor: Centre Hospitalier Universitaire Vaudois; N=27 -> 16 ; Recruiting -> Terminated

Enrollment change • Trial termination • Biosimilar • Melanoma • Oncology

High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - P2; N=30; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Trial primary completion date: Feb 2017 ➔ Feb 2018

Trial primary completion date • Biosimilar • Melanoma • Oncology • Reperfusion Injury

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours (clinicaltrials.gov) - P1/2; N=79; Not yet recruiting; Sponsor: NCIC Clinical Trials Group

New P1/2 trial • Biosimilar • Colorectal Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology

Agenus: Jefferies Global Healthcare Conference (Agenus Inc.) - Anticipated data from P3 trial (NCT00796445) for melanoma in mid-2015

Anticipated P3 data • Melanoma

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3; N=2278; Terminated; Sponsor: GlaxoSmithKline; Active, not recruiting -> Terminated

Trial termination • Biosimilar • Non Small Cell Lung Cancer • Oncology

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma (clinicaltrials.gov) - P1; N=34; Active, not recruiting; Sponsor: GlaxoSmithKline; Trial primary completion date: Aug 2014 ->Jul 2015

Trial primary completion date • Biosimilar • Melanoma • Oncology

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC (clinicaltrials.gov) - P2; N=14; Terminated; Sponsor: H. Lee Moffitt Cancer Center and Research Institute; Active, not recruiting ➔ Terminated; Treatment Ineffective

Clinical • Trial termination • PCR

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3; N=2278; Terminated; Sponsor: GlaxoSmithKline; Phase classification: P2/3 ➔ P3

Clinical • Phase classification

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (clinicaltrials.gov) - P2; N=44; Completed; Sponsor: M.D. Anderson Cancer Center; N=30 ➔ 44

Clinical • Enrollment change

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2/3; N=2278; Terminated; Sponsor: GlaxoSmithKline; Phase classification: P3 ➔ P2/3

Clinical • Phase classification